Cost-effective detection of non-antidouble-stra]nded DNA antinuclear antibody specificities in daily clinical practice

Rheumatology

Volumn 45, Issue 5, 2006, Pages 629-635

  Vos, P A J M ^a   Bast, E J E G ^a   Derksen, R H W M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Antinuclear antibodies; ENA; Health economics

Indexed keywords

ANTINUCLEAR ANTIBODY; CELL NUCLEUS ANTIGEN; DNA ANTIBODY;

ADOLESCENT; ADULT; AGED; ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ARTHRITIS; ARTICLE; AUTOIMMUNE DISEASE; AUTOMATION; BLOOD SAMPLING; CHILD; CLINICAL FEATURE; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC VALUE; FEMALE; HUMAN; IMMUNOASSAY; IMMUNOFLUORESCENCE; INFANT; MAJOR CLINICAL STUDY; MALE; MIXED CONNECTIVE TISSUE DISEASE; POLYMYOSITIS; PRIORITY JOURNAL; SCLERODERMA; SCREENING; SEROLOGY; SJOEGREN SYNDROME; SYMPTOM; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, ANTINUCLEAR; AUTOIMMUNE DISEASES; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; DNA; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HEALTH CARE COSTS; HUMANS; IMMUNOASSAY; INFANT; MIDDLE AGED; NETHERLANDS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 33646185074     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kei260     Document Type: Article

References (12)

1. Klippel JH, Crofford LJ, Stone JH, Weynand CM. Primer on the rheumatic diseases, 12th edn. Atlanta: Arthritis Foundation, 2001.
2. Alarcon-Segovia D, Cardiel MH. Comparison between 3 diagnostic criteria for mixed connective tissue disease. Study of 593 patients. J Rheumatol 1989;16:328-34.
3. Keech CL, Howarth S, Coates T, Rischmueller M, McCluskey J, Gordon TP. Rapid and sensitive detection of anti-Ro (SS-A) antibodies by indirect immunofluorescence of 60kDa Ro HEp-2 transfectants. Pathology 1996;28:54-7.
4. Powell FC, Winkelmann RK, Venencie-Lemarchand F, Spurbeck JL, Schroeter AL. The anticentromere antibody: Disease specificity and clinical significance. Mayo Clin Proc 1984;59:700-6.
5. Slater CA, Davis RB, Shmerling RH. Antinuclear antibody testing. A study of clinical utility. Arch Intern Med 1996;156:1421-5.
6. Lopez-Longo FJ, Rodriguez-Mahou M, Escalona-Monge M, Gonzalez CM, Monteagudo I, Carreno-Perez L. Simultaneous identification of various antinuclear antibodies using an automated multiparameter line immunoassay system. Lupus 2003;12:623-9.
7. Sharp GC, Irvin WS, Tan EM, Gould RG, Hoffman HR. Mixed connective tissue disease-an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med 1972;52:148-59.
8. van Venrooij WJ, Charles P, Maini RN. The consensus workshops for the detection of autoantibodies to intracellular antigens in rheumatic diseases. J Immunol Methods 1991;140:181-9.
9. Meheus L, van Venrooij WJ, Wiik A el al. Multicenter validation of recombinant, natural and synthetic antigens used in a single multiparameter assay for the detection of specific anti-nuclear autoantibodies in connective tissue disorders. Clin Exp Rheumatol 1999;17:205-14.
10. Pottel H, Wiik A, Locht H et al. Clinical optimization and multicenter validation of antigen-specific cut-off values on the INNO-LIA ANA update for the detection of autoantibodies in connective tissue disorders. Clin Exp Rheumatol 2004;22:579-88.
11. Hoffman IE, Peene I, Cebecauer L et al. Presence of rheumatoid factor and antibodies to citrullinated peptides in systemic lupus erythematosus. Ann Rheum Dis 2005;64:330-2.
12. Hoffman IE, Peene I, Veys EM, De Keyser F. Detection of specific antinuclear reactivities in patients with negative anti-nuclear antibody immunofluorescence screening tests. Clin Chem 2002;48:2171-6.